Total Payments
$1,226
2022 Payments
$60.68
Companies
21
Transactions
69
Medicare Patients
2,105
Medicare Billing
$281,958
Payment Breakdown by Category
Food & Beverage$998.09 (81.4%)
Education$228.17 (18.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $998.09 | 64 | 81.4% |
| Education | $228.17 | 5 | 18.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $174.53 | 5 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $144.54 | 14 | $0 (2019) |
| Celgene Corporation | $134.36 | 8 | $0 (2021) |
| Exelixis Inc. | $130.00 | 5 | $0 (2020) |
| Amgen Inc. | $122.50 | 7 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $78.01 | 5 | $0 (2020) |
| Janssen Biotech, Inc. | $59.73 | 2 | $0 (2018) |
| GENZYME CORPORATION | $52.80 | 3 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $41.70 | 2 | $0 (2019) |
| Puma Biotechnology, Inc. | $39.74 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $60.68 | 2 | Amgen Inc. ($32.92) |
| 2021 | $57.17 | 3 | Celgene Corporation ($19.58) |
| 2020 | $130.42 | 5 | Exelixis Inc. ($100.69) |
| 2019 | $302.09 | 20 | AstraZeneca Pharmaceuticals LP ($36.28) |
| 2018 | $643.33 | 37 | Takeda Pharmaceuticals U.S.A., Inc. ($144.09) |
| 2017 | $32.57 | 2 | Celgene Corporation ($18.03) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/16/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $27.76 | General |
| Category: Oncology | ||||||
| 02/14/2022 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $32.92 | General |
| Category: Oncology | ||||||
| 11/29/2021 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Oncology | ||||||
| 10/22/2021 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $19.27 | General |
| 03/19/2021 | Celgene Corporation | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $19.58 | General |
| Category: Oncology | ||||||
| 09/08/2020 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 09/08/2020 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $33.00 | General |
| Category: Oncology | ||||||
| 09/08/2020 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $26.49 | General |
| Category: Oncology | ||||||
| 03/03/2020 | Novartis Pharmaceuticals Corporation | GLEEVEC (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2020 | Amgen Inc. | — | Education | In-kind items and services | $16.24 | General |
| 12/13/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $10.92 | General |
| 08/02/2019 | Kyowa Kirin, Inc. | POTELIGEO (Drug), SANCUSO | Food and Beverage | In-kind items and services | $11.36 | General |
| Category: MONOCLONAL ANTIBODY | ||||||
| 07/26/2019 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), SANDOSTATIN, VOTRIENT | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Oncology | ||||||
| 07/22/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.83 | General |
| Category: Oncology | ||||||
| 07/17/2019 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Oncology | ||||||
| 07/08/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Oncology | ||||||
| 06/19/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $14.58 | General |
| 05/10/2019 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Oncology | ||||||
| 05/07/2019 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Oncology | ||||||
| 03/27/2019 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2019 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug), Nexavar | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Oncology | ||||||
| 03/15/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Oncology | ||||||
| 03/13/2019 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $11.01 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 442 | 801 | $106,192 | $60,490 |
| 2022 | 6 | 482 | 893 | $114,458 | $65,172 |
| 2021 | 7 | 631 | 1,133 | $134,769 | $85,498 |
| 2020 | 7 | 550 | 1,028 | $118,217 | $70,798 |
Total Patients
2,105
Total Services
3,855
Medicare Billing
$281,958
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 78 | 177 | $21,948 | $13,521 | 61.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 58 | 133 | $17,834 | $9,528 | 53.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 64 | 134 | $13,400 | $8,800 | 65.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 61 | 68 | $13,328 | $7,375 | 55.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 40 | $7,320 | $4,735 | 64.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 62 | 98 | $8,308 | $4,305 | 51.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 29 | $8,352 | $4,076 | 48.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 80 | $8,062 | $3,492 | 43.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 28 | $5,246 | $3,214 | 61.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 14 | 14 | $2,394 | $1,444 | 60.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 98 | 258 | $32,501 | $19,680 | 60.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 127 | $16,899 | $9,311 | 55.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 92 | 182 | $15,524 | $8,669 | 55.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 44 | $12,522 | $6,795 | 54.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 65 | 104 | $10,400 | $6,035 | 58.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 44 | 48 | $9,370 | $5,217 | 55.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 28 | 36 | $6,588 | $3,816 | 57.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 54 | 76 | $7,360 | $3,489 | 47.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 18 | $3,294 | $2,159 | 65.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 102 | 235 | $27,902 | $18,716 | 67.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 134 | 262 | $21,211 | $13,821 | 65.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 58 | 149 | $17,367 | $11,375 | 65.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 38 | 75 | $12,564 | $8,563 | 68.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 80 | 134 | $13,400 | $7,874 | 58.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 43 | 44 | $11,572 | $6,808 | 58.8% |
About Dr. Hosam Hakim, M.D
Dr. Hosam Hakim, M.D is a Internal Medicine healthcare provider based in Grosse Pointe Woods, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2012. The National Provider Identifier (NPI) number assigned to this provider is 1619228483.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hosam Hakim, M.D has received a total of $1,226 in payments from pharmaceutical and medical device companies, with $60.68 received in 2022. These payments were reported across 69 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($998.09).
As a Medicare-enrolled provider, Hakim has provided services to 2,105 Medicare beneficiaries, totaling 3,855 services with total Medicare billing of $281,958. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Grosse Pointe Woods, MI
- Active Since 09/20/2012
- Last Updated 06/19/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619228483
Products in Payments
- VELCADE (Drug) $111.24
- Cabometyx (Drug) $88.80
- OPDIVO (Biological) $81.16
- Abraxane (Drug) $60.97
- ZYTIGA (Drug) $59.73
- Pomalyst (Drug) $53.81
- LUMAKRAS (Drug) $51.24
- VYXEOS (Drug) $41.70
- Nerlynx (Drug) $39.74
- Blincyto (Biological) $38.77
- ZEJULA (Drug) $36.33
- IMFINZI (Drug) $36.28
- JEVTANA (Drug) $33.53
- NINLARO (Drug) $29.61
- BRUKINSA (Drug) $27.76
- RYDAPT (Drug) $27.50
- SPRYCEL (Drug) $26.11
- TASIGNA (Drug) $21.48
- ONUREG (Drug) $19.58
- Xofigo (Drug) $18.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Grosse Pointe Woods
Zaynab Al-Sagri, Md, MD
Internal Medicine — Payments: $1,735
Internal Medicine $1,735
Dr. Hussein Gharib, Md, MD
Internal Medicine — Payments: $668.43
Internal Medicine $668.43
Thomas Loss, Md, MD
Internal Medicine — Payments: $552.66
Internal Medicine $552.66
Jeremy Henson, Md, MD
Internal Medicine — Payments: $486.72
Internal Medicine $486.72
Zainab Muslehuddin
Internal Medicine — Payments: $373.69
Internal Medicine $373.69
Jacob Compton, Do, DO
Internal Medicine — Payments: $273.85
Internal Medicine $273.85